An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers.

ABSTRACT: Human neuroendocrine (NE) cancers range from relatively indolent to highly aggressive. In this study, we combine functional genomics with metabolomics to identify features of NE cancers associated with a poor outcome. Analysis of GeneChip datasets of primary prostate tumors, as well as lymph node and liver metastases from transgenic mice with a NE cell cancer, plus derived NE cell lines yielded a signature of 446 genes whose expression is enriched in neoplastic mouse prostatic NE cells. This signature was used for in silico metabolic reconstructions of NE cell metabolism, directed liquid chromatography/tandem MS analysis of metabolites in prostatic NE tumors and cell lines, and analysis of GeneChip datasets of human NE tumors with good or poor prognoses. The results indicate that a disting

SUBMITTER: Ippolito JE 

PROVIDER: S-EPMC1169236 | biostudies-literature | 2005 Jul

REPOSITORIES: biostudies-literature